Drug Trial Radar · NCT02944487
A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Oct 2002
Primary completion
Dec 2002
Study completion Dec 2002
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study were to evaluate the safety and tolerability of lucerastat, and to determine its pharmacokinetic profile as single oral doses at different strengths.
Conditions
- Healthy Subjects
Interventions
LucerastatDrug
Hard gelatin capsule for oral administration containing lucerastat
PlaceboDrug
Matching placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: From baseline up to 7 days post-administration
- Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
- Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
- Time to reach Cmax (tmax) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
- Time to reach Cmax (tmax) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
- Area under the plasma concentration-time curves (AUC) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
- Area under the plasma concentration-time curves (AUC) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
- Terminal elimination half-life (t1/2) of lucerastat after single ascending doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
- Terminal elimination half-life (t1/2) of lucerastat after two daily doses of lucerastatTime frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigator Site
Tranent, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.